Compounds and methods for modulating vascular injury

Patent metadata

Field	Value
Publication number	US-10111847-B2
Application number	US-201615255778-A
Country	US
Kind code	B2
Filing date	Sep 2, 2016
Priority date	Sep 10, 2012
Publication date	Oct 30, 2018
Grant date	Oct 30, 2018

Abstract

Methods of modulating healing response to vascular injury and/or vascular scarring in a subject are provided. As such, aspects of the disclosure relate to the use of pro-resolving lipid mediators to modulate inflammation and/or restenosis of a vascular wall. Another aspect of the disclosure relates to the use of pro-resolving lipid mediators to modulate a biological activity of vascular smooth muscle cells (VSMC) or vascular endothelial cells (VEC). Pro-resolving lipid mediators that fmd use in the subject methods include derivatives of omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids, such as resolvins, protectins, lipoxins and maresins and their therapeutically stable analogs. Also provided are vascular devices and compositions for use in the subject methods. Such methods, devices and compositions fmd use in a variety of applications, including applications related to treatment of vascular injuries and vascular scarring (e.g., restenosis), and applications related to chronic inflammatory diseases of the vascular wall.

First claim

What is claimed is:

1. A method of reducing inflammatory response of vascular smooth muscle cells of a vascular wall to vascular injury or restenosis of a vascular wall following injury, the method comprising:
positioning a vascular device at or adjacent the vascular wall,
wherein the vascular device releases a pro-resolving lipid mediator in an amount sufficient to reduce the inflammatory response to the vascular injury or restenosis of the vascular wall,
wherein the vascular device is a stent or a perivascular wrap,
wherein the pro-resolving lipid mediator comprises Maresin-1, RvD1, or RvD2.

2. The method of claim 1 , wherein the pro-resolving lipid mediator is Maresin-1.

3. The method of claim 1 , wherein the method resolves vascular wall inflammation.

4. The method of claim 1 , wherein method reduces restenosis of the vascular wall.

5. The method of claim 1 , wherein the pro-resolving lipid mediator is RvD1.

6. The method of claim 1 , wherein the pro-resolving lipid mediator is RvD2.

7. The method of claim 1 , wherein the stent comprises a surface comprising a coating comprising a nanotube comprising nitinol.

8. The method of claim 1 , wherein the perivascular wrap comprises a biodegradable polymer comprising polycaprolactone.

Assignees

• Univ California
• Brigham & Womens Hospital Inc

Inventors

• Conte Michael S
• Serhan Charles N
• Desai Tejal A

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/202 Primary

  having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557) · CPC title